Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Biofrontera AGLTS:0DOL +0.44%16 Net Debt Paydown Yield % is 2.29% as of Jul. 15, 2026, which is 127% above its 10-year median of 1.01. GuruFocus rates LTS:0DOL with a GF Score™ of 16/100 and a GF Value™ of €2.41 (Fairly Valued). The stock has 4 warning signs investors should review. Among 922 Drug Manufacturers companies, Biofrontera AG ranks better than 78.96% on this metric.
Net Debt Paydown Yield % is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. It is a measure of a company's willingness and ability to reduce its debt.
As of today, Biofrontera AG's Net Debt Paydown Yield % was 2.29%.
Biofrontera AG (LTS:0DOL) Net Debt Paydown Yield % Explanation
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced. In other words, it is a measure of the willingness and ability of a firm's management to pay down debt. Companies that have high debt paydown yields indicate that they are more aggressive with paying down debt.
In the calculation of Net Debt Paydown Yield %, we use the reductions of TTM average total debt one-year-ago and TTM average total debt at present, divided by its Market Cap.
Biofrontera AG Net Debt Paydown Yield % Related Terms
Biofrontera AG Net Debt Paydown Yield % Historical Data
* Premium members only.
The historical data trend for Biofrontera AG's Net Debt Paydown Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0DOL vs ZTS, UTHR, VTRS: Net Debt Paydown Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Biofrontera AG's Net Debt Paydown Yield %, along with its competitors' market caps and Net Debt Paydown Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biofrontera AG Net Debt Paydown Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Biofrontera AG's Net Debt Paydown Yield % distribution charts can be found below:
* The bar in red indicates where Biofrontera AG's Net Debt Paydown Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Net Debt Paydown Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
What does a Net Debt Paydown Yield % of 2.29% mean?
Biofrontera AG (LTS:0DOL) has a Net Debt Paydown Yield % of 2.29% as of Jul. 15, 2026. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on Biofrontera AG and its competitors. This is 127% above median its historical median of 1.01. According to the industry distribution chart, Biofrontera AG ranks #194 out of 922 companies in the Drug Manufacturers industry, placing it in the top 21%.
Is Biofrontera AG's Net Debt Paydown Yield % too high?
Biofrontera AG's current Net Debt Paydown Yield % of 2.29% is 127% above median its 10-year median of 1.01. Based on the distribution chart, Biofrontera AG ranks #194 out of 922 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Biofrontera AG has a GF Score™ of 16/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Biofrontera AG's Net Debt Paydown Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Biofrontera AG ranks #194 out of 922 companies for Net Debt Paydown Yield %. This places Biofrontera AG in the top 21% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Debt Paydown Yield % for a Drug Manufacturers company?
A good Net Debt Paydown Yield % depends on the Drug Manufacturers industry context. However, Net Debt Paydown Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Debt Paydown Yield % mean?
A high Net Debt Paydown Yield % can signal that a stock is expensive relative to its fundamentals. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on Biofrontera AG and its competitors. Biofrontera AG's current Net Debt Paydown Yield % is 2.29%, which is 127% above median its own 10-year median of 1.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biofrontera AG stock overvalued right now?
Based on GuruFocus' analysis, Biofrontera AG (LTS:0DOL) is currently considered Fairly Valued. The stock's GF Value™ is €2.41, compared to a current price of €2.28 — trading 5.4% below its estimated fair value. The current Net Debt Paydown Yield % is 2.29%, which is 127% above median its 10-year median of 1.01. Biofrontera AG's overall GF Score™ is 16/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Debt Paydown Yield % calculated?
Net Debt Paydown Yield % is calculated from a company's financial statements. For Biofrontera AG (LTS:0DOL), the current Net Debt Paydown Yield % is 2.29% as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biofrontera AG (LTS:0DOL) Overvalued in 2026?
Based on GuruFocus' analysis, Biofrontera AG stock appears to be undervalued.
The current stock price of €2.28 is trading 5.4% below its estimated GF Value™ of €2.41.
GuruFocus considers Biofrontera AG to be Fairly Valued.
Key valuation signals for LTS:0DOL:
Net Debt Paydown Yield %: 2.29% (127% above median its 10-year median of 1.01)
GF Value™: €2.41 vs. price of €2.28 (5.4% below fair value)
No single metric tells the full story. See the LTS:0DOL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biofrontera AG is active in the field of healthcare. It manufactures pharmaceutical products, especially medical cosmetics and dermatological drugs for the care and treatment of skin diseases. Its suite of products includes the prescription drugs Ameluz and BF-RhodoLED and BF-RhodoLED XL, for the treatment of actinic keratosis and Belixos, for the regenerative care of reddened and inflamed skin. Geographically, the company generates maximum revenue from Germany, and the rest from Spain, the United Kingdom, the rest of Europe, and other regions.
16GF Score
Get the complete analysis for LTS:0DOL
Net Debt Paydown Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0DOL has been successfully added to your 
